AbbVie Wins EU Approval for RINVOQ in Pediatric JIA
North Chicago, Illinois, U.S., September 22, 2026 AbbVie has announced that the European Commission has approved RINVOQ® (upadacitinib) for...
JAK inhibitor
Advertisement
Specialised Therapeutics Expands Opzelura Partnership in Australia
Singapore, September 21, 2026 Specialised Therapeutics (ST) has expanded its existing partnership with Incyte to include ruxolitinib cream (Opzelura®)...
LEO Pharma Gains Positive CHMP Opinion for Anzupgo
BALLERUP, Denmark — September 18, 2026 LEO Pharma announced that the European Medicines Agency’s Committee for Medicinal Products for...
Orsini Partners With Priovant to Support LISRAYA Access
ELK GROVE VILLAGE, Illinois, Aug 28, 2026 Orsini announced that it will serve as a specialty pharmacy partner for...
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
Advertisements
Karyopharm Eyes Accelerated FDA Approval for Selinexor
NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...
AbbVie Secures EU Approval for RINVOQ in Severe Alopecia Areata
NORTH CHICAGO, Ill., July 29, 2026 AbbVie announced that the European Commission (EC) has approved RINVOQ® (upadacitinib) for the...
Incyte Secures EU Approval for Opzelura Cream in Atopic Dermatitis
WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...
Castle Biosciences Wins NY Approval for AdvanceAD-Tx Test
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx™ test has received assay approval from...
Roche Enspryng Gains FDA Priority Review for TED Treatment
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Advertisement
